<DOC>
	<DOCNO>NCT01531244</DOCNO>
	<brief_summary>This phase I/II trial study safety , best dose effectiveness target gene therapy combine isolated limb infusion ( ILI ) melphalan dactinomycin treat patient advanced extremity melanoma remove surgery . Adding gene therapy standard chemotherapy regimen isolate limb may enhance anti-cancer effect induce systemic immune response tumor cell .</brief_summary>
	<brief_title>Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy Advanced , Unresectable Extremity Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>Patient must histologically cytologically confirm diagnosis melanoma advance , unresectable primary transit metastasis Patient must measurable disease defined lesion accurately measure least one dimension ( long diameter record ) &gt; = 10 mm caliper measurement superficial lesion compute tomography ( CT ) scan deep lesion ; additionally , patient must evidence disease beyond affected extremity positron emission tomography ( PET ) /CT scan Patients may undergone previous systemic chemotherapy treatment free period &gt; 4 week prior enrol clinical trial Patient must &gt; 18 year age.Patient must Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 , Karnofsky &gt; = 60 % Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin = &lt; 1.5 x institutional upper limit normal ( IULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3.0 x IULN Creatinine within normal institutional limit OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , must inform treat physician immediately Patient ( legally authorize representative applicable ) must able understand willing sign institutional review board ( IRB ) approve write informed consent document Patients must previous oncolytic viral therapy Patient must receive investigational agent Patient must know brain metastasis ; patient know brain metastasis must exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event Patient must history allergic reaction attribute compound similar chemical biologic composition melphalan dactinomycin agent use study Patient must uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Patient must pregnant and/or breastfeed Patient must know human immunodeficiency virus ( HIV ) positive otherwise immunocompromised ( i.e. , patient undergone organ/bone marrow transplant immunosuppression , patient recently undergone treatment toxic chemotherapy another malignancy , etc . ) risk complication use adenovirus therapy patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>